HomeCompareCBLI vs PLD

CBLI vs PLD: Dividend Comparison 2026

CBLI yields 63.09% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.15M in total portfolio value· pulled ahead in Year 9
10 years
CBLI
CBLI
● Live price
63.09%
Share price
$3.17
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$757.3K
Annual income
$183,899.77
Full CBLI calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — CBLI vs PLD

📍 PLD pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCBLIPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CBLI + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CBLI pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CBLI
Annual income on $10K today (after 15% tax)
$5,362.78/yr
After 10yr DRIP, annual income (after tax)
$156,314.80/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $3,881,801.61/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CBLI + PLD for your $10,000?

CBLI: 50%PLD: 50%
100% PLD50/50100% CBLI
Portfolio after 10yr
$3.33M
Annual income
$2,467,312.47/yr
Blended yield
74.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

CBLI
Analyst Ratings
3
Buy
1
Hold
Consensus: Buy
Altman Z
435.1
Piotroski
1/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CBLI buys
0
PLD buys
0
No recent congressional trades found for CBLI or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCBLIPLD
Forward yield63.09%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$757.3K$5.91M
Annual income after 10y$183,899.77$4,750,725.19
Total dividends collected$633.8K$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: CBLI vs PLD ($10,000, DRIP)

YearCBLI PortfolioCBLI Income/yrPLD PortfolioPLD Income/yrGap
1$17,009$6,309.15$11,241$540.96+$5.8KCBLI
2$28,229$10,029.27$13,019$991.13+$15.2KCBLI
3$45,761$15,556.06$15,801$1,870.97+$30.0KCBLI
4$72,532$23,567.66$20,609$3,701.21+$51.9KCBLI
5$112,521$34,911.29$29,919$7,867.97+$82.6KCBLI
6$171,013$50,615.56$50,631$18,617.74+$120.4KCBLI
7$254,878$71,894.60$105,528$51,352.20+$149.3KCBLI
8$372,862$100,142.13$287,364$174,449.42+$85.5KCBLI
9← crossover$535,876$136,914.14$1,081,760$774,280.77$545.9KPLD
10$757,287$183,899.77$5,908,209$4,750,725.19$5.15MPLD

CBLI vs PLD: Complete Analysis 2026

CBLIStock

Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. The company is headquartered in Buffalo, New York and currently employs 15 full-time employees. The firm is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.

Full CBLI Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this CBLI vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CBLI vs SCHDCBLI vs JEPICBLI vs OCBLI vs KOCBLI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.